biotech / news / / Benzinga
Eli Lilly reported first-quarter adjusted earnings of $8.55 per share.
Eli Lilly's Q1 sales grew 56% year over year, exceeding analyst expectations by over $2 billion.
KEY POINTS
- FDA approved Foundayo, the only GLP-1 pill usable at any time without food or water restrictions.
- Eli Lilly raised 2026 sales guidance to $82–$85 billion, above Wall Street estimates.
- The company announced acquisitions of Kelonia Therapeutics and Ajax Therapeutics totaling up to $9.3 billion.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →